Article
Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.
Cancer science - 1 Jul 2009
Jin Yanli, Chen Qi, Shi Xianping, Lu Zhongzheng, Cheng Chao, Lai Yingrong, Zheng Qin, Pan Jingxuan
Abstract excerpt
Gain-of-function mutations of the receptor tyrosine kinase KIT can cause systemic mastocytosis (SM) and gastrointestinal stromal tumors. Most of the constitutively active KIT can be inhibited by imatinib; D816V KIT cannot. In this study, we investigated the activity of triptolide, a diterpenoid isolated from the Chinese herb Tripterygium wilfordii Hook. f., in cells expressing mutant KIT, including D816V KIT....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.